Axsome Therapeutics Inc (AXSM.OQ)
AXSM.OQ on NASDAQ Stock Exchange Global Market
2.45USD
17 Aug 2018
2.45USD
17 Aug 2018
Change (% chg)
$0.15 (+6.52%)
$0.15 (+6.52%)
Prev Close
$2.30
$2.30
Open
$2.35
$2.35
Day's High
$2.45
$2.45
Day's Low
$2.33
$2.33
Volume
7,061
7,061
Avg. Vol
29,457
29,457
52-wk High
$6.45
$6.45
52-wk Low
$2.05
$2.05
Select another date:
Tue, May 8 2018
BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19
* AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation
* AXSOME THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF AXS-05 IN SMOKING CESSATION Source text for Eikon: Further company coverage:
BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER
BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31
* AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial
* AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN
Select another date: